
GSK: favorable decision in Zantac litigation in US
(CercleFinance.com) - GSK has announced that it is delighted with today's verdict by the jury in the Joiner case in Illinois state court, which ruled in favour of the company.
This result is in line with the scientific consensus that there is no consistent or reliable evidence that Zantac (ranitidine) increases the risk of cancer, as confirmed by 16 epidemiological studies, GSK says, indicating that it will continue to defend itself vigorously against all other claims.
Prior to this verdict, the court had rejected the plaintiff's claim for punitive damages, GSK adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This result is in line with the scientific consensus that there is no consistent or reliable evidence that Zantac (ranitidine) increases the risk of cancer, as confirmed by 16 epidemiological studies, GSK says, indicating that it will continue to defend itself vigorously against all other claims.
Prior to this verdict, the court had rejected the plaintiff's claim for punitive damages, GSK adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.